Related Experiment Video

Updated: Aug 11, 2026

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

The influence of antineoplaston A5 on the central dopaminergic structures

M Juszkiewicz1, A Chodkowska, S R Burzynski

  • 1Department of Pharmacology, Medical Academy, Lublin, Poland.

Drugs Under Experimental and Clinical Research
|January 1, 1994
PubMed

Insights

Antineoplaston A5, a naturally occurring agent, shows promise in treating Parkinson's disease symptoms by stimulating central dopaminergic receptors. This study investigated its effects on animal models, revealing significant improvements in motor functions and neurotransmitter levels.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Antineoplastons are endogenous cytodifferentiating agents found in blood, tissues, and urine.
  • Antineoplaston A5 has shown potential in improving parkinsonian symptoms in cancer patients.

Purpose of the Study:

  • To investigate the influence of Antineoplaston A5 on central dopaminergic structures.
  • To evaluate the effects of Antineoplaston A5 on motor activity and neurotransmitter levels in animal models.

Main Methods:

  • Administration of Antineoplaston A5 to mice and rats at varying doses.
  • Assessment of spontaneous locomotor activity, amphetamine-induced yawning and erections, and catalepsy.
  • Analysis of brain catecholamine (dopamine and noradrenaline) levels and utilization, including response to haloperidol and apomorphine.

Main Results:

  • Antineoplaston A5 demonstrated stimulation of central dopaminergic receptors.
  • It reduced haloperidol-induced catalepsy and increased apomorphine-induced yawning.
  • Biochemical analysis revealed increased brain dopamine and noradrenaline concentrations and decreased utilization.

Conclusions:

  • Antineoplaston A5 exhibits a stimulatory effect on central dopaminergic pathways.
  • The findings suggest Antineoplaston A5 has potential therapeutic applications for conditions involving dopaminergic dysfunction, such as Parkinson's disease.

More Related Videos

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector08:33

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis06:09

Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis

Published on: February 2, 2021

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...